Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Fisher & Paykel Healthcare raises guidance – shares climb to record high

Fisher & Paykel Healthcare raised its guidance for fiscal year 2027 and now expects revenue of NZ$2.47–2.57bn and net profit after tax of NZ$525–565m. For H1 2027 a net profit of around NZ$280m is forecast. The lift was attributed to strong demand in the hospital division, efficiency and margin improvements, and an IEEPA tariff refund of NZ$23m, after which the stock rose to record highs in Australia and New Zealand. » More on de.investing.com
Fisher & Paykel Healthcare reports strong H2 2026 with revenue and profit growth, shares slip slightly

Fisher & Paykel Healthcare posted operating revenue of NZD 2.3 billion (+14%) and net profit after tax of NZD 468.5 million (+24%) for H2 of fiscal 2026, with gross margin rising to 63.7% and operating cash flow at NZD 663 million (+21%). Despite the strong metrics, the share fell 0.43% and is trading near its 52-week low. Management and the report cite manufacturing efficiency and product innovation as drivers but warn of pressures from US tariffs, currency effects, hedging losses of NZD 21 million and supply-chain risks. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, FISHER + PAYKEL HEALTH. has already paid €0.19 in dividends. The last payout was in July.

Financials

In the last quarter, FISHER + PAYKEL HEALTH. had revenue of €620.14m and net profit of €127.94m

(EUR)	March 2026	YoY
Revenue	620.14m	-
Gross profit	402.06m	-
Net profit	127.94m	-
EBITDA	226.59m	-

Fundamentals

Metric	Value
Market capitalization	€14.21bn
Number of shares	588.27m
52-week high/low	€25.03 - €16.52
Dividend yield	1.30%
Dividends TTM	€0.30
Beta	0.93
P/E ratio	60.35
PEG ratio	1.70
P/B ratio	13.40
P/S ratio	12.12

Company profile

Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It also provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company offers Airvo 2, a humidified nasal high flow system; Optiflow, a nasal high flow therapy; and F&P 850 System, a noninvasive and invasive ventilation system. In addition, it provides infant respiratory products, such as resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products, including humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, humidifiers, and accessories. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.